Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger Than Age 18 Years
| Autor: | Carlos Bernardo Tauil, Maria Lucia Brito Ferreira, Maria Iris Moraes Machado, Marcus Goncalves, André Palma da Cunha Matta, Dagoberto Callegaro, Yara Dadalti Fragoso, Soniza Vieira Alves-Leon, Regina Maria Papais-Alvarenga, Amilton Antunes Barreira, Samira Luisa dos Apostolos Pereira, Alessandro Finkelsztejn, Vanessa Daccach Marques, Sidney Gomes |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Drug
Male medicine.medical_specialty Pediatrics Multiple Sclerosis Adolescent media_common.quotation_subject Drug Prescriptions Disability Evaluation FÁRMACOS IMUNOSSUPRESSORES Developmental Neuroscience medicine Humans In patient Adverse effect Child media_common medicine.diagnostic_test business.industry Fingolimod Hydrochloride Multiple sclerosis Magnetic resonance imaging medicine.disease Fingolimod Magnetic Resonance Imaging Clinical trial Neurology Child Preschool Pediatrics Perinatology and Child Health Physical therapy Observational study Female Neurology (clinical) business Brazil Immunosuppressive Agents medicine.drug Follow-Up Studies |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP |
| ISSN: | 1873-5150 |
| Popis: | Background There have been no clinical trials for approval of medications for treating multiple sclerosis in patients younger than age 18 years. All treatments are based on personal experience and data from open observational studies. Fingolimod is an oral drug for multiple sclerosis that has been shown to be efficient and safe in adults. The aim of our study is to describe patients with multiple sclerosis who started treatment with fingolimod before the age of 18 years. Participants and methods Seventeen patients treated with fingolimod were identified in the Brazilian database of children and adolescents with multiple sclerosis. The average time of use of the drug was 8.6 months. Results Fingolimod showed a good safety and efficacy profile in these patients, all of whom had very active multiple sclerosis. After starting treatment with fingolimod, only one patient had a relapse and a new lesion on magnetic resonance imaging. The patients' degree of disability did not progress. No major adverse events were reported in relation to the first dose of the drug, nor in the short- and medium-term treatment. No patient has been followed for longer than 18 months, thus limiting long-term conclusions. Conclusions Off-label use of fingolimod in patients younger than age 18 years may be a good therapeutic option for multiple sclerosis control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect